Catalyst Pharmaceuticals Announces Top-Line Results of CMS-001, a Phase 3 Trial of Firdapse® (Amifampridine Phosphate) in Patients with Congenital Myasthenic Syndromes (CMS)
Catalyst Pharmaceuticals, Inc. (CPRX)
Last catalyst pharmaceuticals, inc. earnings: 3/16 05:26 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.catalystpharma.com
Company Research
Source: GlobeNewswire
CMS-001 trial is the first and only double-blinded, placebo-controlled study ever conducted in genetically confirmed CMS patients Results in full population across all tested subtypes of CMS did not achieve statistical significance for the primary or secondary endpoints MuSK-Myasthenia Gravis Phase 3 trial and SMA Type-3 proof of concept study both remain on schedule CORAL GABLES, Fla., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a commercial-stage biopharmaceutical company focused on developing innovative therapies for people with ultra-rare debilitating, chronic neuromuscular and neurological diseases, today announced top-line results from CMS-001, a Phase 3 study evaluating amifampridine phosphate for the symptomatic treatment of genetically confirmed Congenital Myasthenic Syndromes (CMS) in adults and children aged 2 years and above. The Company’s lead product, Firdapse® (amifampridine phosphate), is currently approved for the treatm
Show less
Read more
Impact Snapshot
Event Time:
CPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CPRX alerts
High impacting Catalyst Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CPRX
News
- Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock [Yahoo! Finance]Yahoo! Finance
- Are You a Value Investor? This 1 Stock Could Be the Perfect Pick [Yahoo! Finance]Yahoo! Finance
- Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to WorkGlobeNewswire
- Catalyst Pharmaceuticals' (NASDAQ:CPRX) Earnings May Just Be The Starting Point [Yahoo! Finance]Yahoo! Finance
- Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) had its price target raised by analysts at Truist Financial Co. from $30.00 to $36.00. They now have a "buy" rating on the stock.MarketBeat
CPRX
Earnings
- 11/6/24 - Beat
CPRX
Sec Filings
- 11/15/24 - Form 4
- 11/14/24 - Form 144
- 11/14/24 - Form SC
- CPRX's page on the SEC website